Alternating 17β-Estradiol and Aromatase Inhibitor Therapies in Postmenopausal Women With Advanced Endocrine-Resistant ER+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer
Clin. Cancer Res 2023 Jun 01;[EPub Ahead of Print], GN Schwartz, PA Kaufman, KV Giridhar, JD Marotti, MD Chamberlin, BA Arrick, G Makari-Judson, MP Goetz, SM Soucy, F Kolling, E Demidenko, TW MillerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.